# OnCo record inobrodib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/inobrodib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "inobrodib" ;
  schema:name "Inobrodib"@en ;
  schema:alternateName "CCS1477"@en ;
  schema:description "Inobrodib is an experimental pill from CellCentric, in phase 3 trials for relapsed or refractory multiple myeloma."@en ;
  schema:url <https://onco.cc/drugs/inobrodib/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://www.cellcentric.com/clinical-trials/>, <https://www.cellcentric.com/press-release/cellcentric-announces-oversubscribed-220-million-series-d-financing-to-advance-pivotal-trials-of-inobrodib-in-multiple-myeloma/>, <https://clinicaltrials.gov/study/NCT04068597>, <https://clinicaltrials.gov/study/NCT07772024>, <https://clinicaltrials.gov/study/NCT07096778>, <https://clinicaltrials.gov/study/NCT03568656> ;
  onco:status "phase-3" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Small molecule, oral" ;
  onco:cancers <https://onco.cc/cancers/myeloma-relapsed-refractory/> ;
  onco:targets <https://onco.cc/targets/ep300/>, <https://onco.cc/targets/crebbp/> ;
  onco:companies <https://onco.cc/companies/cellcentric/> ;
  onco:trials <https://onco.cc/trials/nct04068597/>, <https://onco.cc/trials/nct07772024/>, <https://onco.cc/trials/nct07096778/>, <https://onco.cc/trials/nct03568656/> .